Atasin 40 mg Tablet (Atorvastatin) – ACI Limited

1. About Atasin 40 mg (Atorvastatin Calcium 40 mg)

Atasin 40 mg Tablet contains Atorvastatin Calcium 40 mg, manufactured by ACI Limited, Bangladesh. This high-intensity statin formulation provides approximately 46–51% reduction in LDL-cholesterol and is the recommended dose for patients requiring aggressive lipid lowering — including all patients with established atherosclerotic cardiovascular disease, very-high-risk T2DM, and familial hypercholesterolaemia.

The PROVE-IT TIMI-22 trial established atorvastatin 40 mg's superiority over lower-intensity statins in ACS patients. The TNT (Treating to New Targets) trial demonstrated that 40 mg further reduced major cardiovascular events compared to 10 mg in stable CAD patients. The CARDS trial (10 mg — primarily) and ASCOT-LLA support statin use in T2DM; for high-risk T2DM, 40 mg is the appropriate high-intensity choice in Bangladesh's cardiovascular patient population.

2. Mechanism of Action

Atorvastatin 40 mg competitively inhibits hepatic HMG-CoA reductase at near-maximal clinical efficacy. The dose-response is logarithmic — successive doublings from 10 mg provide ~6–8% additional LDL-C reduction each step. At 40 mg, approximately 46–51% LDL-C reduction is achieved — classifying this as high-intensity therapy per ACC/AHA 2018 guidelines. Active metabolites extend the effective inhibitory half-life to 20–30 hours, providing sustained 24-hour LDL receptor upregulation.

Pleiotropic benefits are dose-dependent: higher doses produce greater reductions in hsCRP, ICAM-1, fibrinogen, and P-selectin, contributing to plaque stabilisation, endothelial function improvement, and reduced thrombotic tendency beyond LDL-C effects.

3. Indications

• Secondary cardiovascular prevention — all post-MI, post-ACS, established stable CAD, PAD, prior ischaemic stroke patients
• Very-high-risk T2DM — diabetes + target organ damage or + ≥3 major CV risk factors
• Familial hypercholesterolaemia — both heterozygous and homozygous (as part of combination therapy)
• High-risk primary prevention — 10-year CVD risk >20% with LDL target <1.8 mmol/L
• Dose escalation from 20 mg when LDL target not achieved

4. Dosage and Administration

40 mg once daily. Any time of day, with or without food. Recheck LDL-C at 6–8 weeks. If guideline LDL target not reached (e.g. <1.4 mmol/L for ASCVD), add ezetimibe 10 mg or escalate to atorvastatin 80 mg. No renal dose adjustment needed — hepatically cleared. Liver impairment: cautious dose reduction; avoid in severe.

5. Contraindications

• Active liver disease or persistently elevated transaminases (>3× ULN)
• Pregnancy (Pregnancy Category X — teratogenic) and breastfeeding
• Hypersensitivity to atorvastatin or any excipients

6. Warnings and Precautions

Myopathy: Dose-dependent — higher at 40 mg than 10–20 mg. Absolute rhabdomyolysis risk <0.1% in absence of interacting drugs. Risk increases significantly with cyclosporine (contraindicated), strong CYP3A4 inhibitors, gemfibrozil, high-dose niacin, colchicine. Check CK if symptomatic myalgia.

Liver: Dose-dependent transaminase elevations. Monitor LFTs; if ALT >3× ULN on 2 consecutive tests — reduce dose or stop. Avoid in pre-existing liver disease.

Cognitive: Post-marketing reports of memory impairment, confusion. Generally reversible on discontinuation.

7. Side Effects

Common: Myalgia, headache, arthralgia, nasopharyngitis, nausea, constipation, diarrhoea, insomnia, elevated CPK (dose-dependent).

Uncommon: Elevated transaminases, peripheral oedema, neuropathy, alopecia, cognitive symptoms.

Rare: Rhabdomyolysis, IMNM, serious hepatotoxicity, angioedema, lupus-like reaction.

8. Drug Interactions

• Cyclosporine: Contraindicated with 40 mg — maximum atorvastatin 10 mg
• Strong CYP3A4 inhibitors (clarithromycin, itraconazole, HIV PIs): Markedly increase atorvastatin levels — limit atorvastatin to 20 mg, switch to lower CYP3A4-dependent statin if possible
• Gemfibrozil: Avoid — significant myopathy risk via dual OATP1B1/CYP inhibition
• Warfarin: Monitor INR — may potentiate effect
• Colchicine: Caution — additive myopathy risk

9. Atasin 40 mg in Bangladesh's Cardiovascular Burden

Bangladesh faces an accelerating cardiovascular disease epidemic, driven by T2DM (prevalence ~10–12% in adults), hypertension (~25%), smoking, and central obesity. Post-MI and post-ACS patients require indefinite high-intensity statin therapy — Atasin 40 mg provides ACI Limited's quality-assured high-intensity option. Combined with ACE inhibitors, beta-blockers, and antiplatelets, Atasin 40 mg forms a cornerstone of secondary prevention in Bangladeshi cardiology practice. The 2023 Bangladesh Cardiology Society guidelines align with ESC/EAS recommendations for high-intensity statins in all ASCVD patients.

10. Storage

• Store below 30°C, cool and dry, protected from light and moisture. Original blister. Out of reach of children.

Frequently Asked Questions (FAQ)

Q1: Is Atasin 40 mg suitable for use after a heart attack?

Yes — Atasin 40 mg (Atorvastatin 40 mg) is a first-line treatment for all patients following myocardial infarction (heart attack) or acute coronary syndrome (ACS). This is based on multiple landmark trials: PROVE-IT TIMI-22 showed intensive atorvastatin (40–80 mg) vs moderate-intensity pravastatin (40 mg) reduced MACE by 16% in post-ACS patients. Current guidelines universally recommend high-intensity statin therapy (atorvastatin 40–80 mg) for all post-ACS patients regardless of baseline LDL, to achieve LDL <1.4 mmol/L with ≥50% reduction from baseline. Atasin 40 mg should be started in hospital and continued indefinitely post-MI.

Q2: How does Atasin 40 mg compare to Rosuvastatin for LDL reduction?

Rosuvastatin is a more potent statin per mg than atorvastatin. Rosuvastatin 20 mg provides comparable LDL-C reduction (~47–52%) to atorvastatin 40 mg (~46–51%). Both are high-intensity statins by ACC/AHA criteria. Key differences: (1) Atorvastatin is primarily CYP3A4-metabolised; rosuvastatin minimally metabolised (BCRP/OATP substrate) — different drug interaction profiles; (2) Atorvastatin has more long-term trial data (PROVE-IT, TNT, IDEAL, ASCOT, CARDS) compared to rosuvastatin (JUPITER, AURORA); (3) Both equally recommended in current guidelines. Choice depends on comorbidities, drug interactions, tolerability, and cost. ACI's Atasin 40 mg is a well-established, cost-effective high-intensity option in Bangladesh.

Q3: Can Atasin 40 mg cause liver damage?

Clinically significant liver damage from atorvastatin is rare. Transient, asymptomatic elevations in liver transaminases (ALT/AST) occur in approximately 0.5–2% of patients on high-dose atorvastatin — these typically resolve with dose reduction. True severe hepatotoxicity (liver failure) is exceedingly rare and not clearly causally established for statins in current evidence. Pre-treatment LFT measurement is recommended; routine monitoring thereafter is suggested if symptomatic. Atorvastatin should be avoided in patients with active liver disease, chronic hepatitis, or alcohol-related liver disease. Regular alcohol consumption does increase hepatotoxicity risk with high-dose statins.

Q4: What is the target LDL when taking Atasin 40 mg?

LDL targets depend on cardiovascular risk category per ESC/EAS 2019 and ACC/AHA 2018 guidelines: Very high risk (established ASCVD, T2DM + end-organ damage, FH + risk factor): LDL <1.4 mmol/L (55 mg/dL) and ≥50% reduction from baseline. High risk (T2DM with ≥1 risk factor, severe CKD, 10-year CVD risk ≥10%): LDL <1.8 mmol/L (70 mg/dL) and ≥50% reduction. Moderate risk (10-year CVD risk 5–10%): LDL <2.6 mmol/L (100 mg/dL). Atasin 40 mg (46–51% LDL reduction) achieves targets in most high-risk patients — those not meeting very-high-risk LDL <1.4 mmol/L should add ezetimibe 10 mg.